(Q39277209)

10 September 2017

title

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma (English)

1 reference

10 September 2017

5

Hermann Einsele

1 reference

10 September 2017

Torsten Steinbrunn

1

1 reference

10 September 2017

Thorsten Stühmer

2

1 reference

10 September 2017

Cyrus Sayehli

3

1 reference

10 September 2017

Manik Chatterjee

4

1 reference

10 September 2017

Ralf C Bargou

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

17 September 2012

1 reference

British Journal of Haematology

10 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

10 September 2017

volume

159

1 reference

10 September 2017

issue

4

1 reference

10 September 2017

page(s)

430-440

1 reference

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

10 September 2017

cites work

1 reference

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

Analysis of PTEN deletions and mutations in multiple myeloma

21 January 2018

1 reference

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells

21 January 2018

1 reference

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

21 January 2018

1 reference

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.

21 January 2018

1 reference

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

21 January 2018

1 reference

21 January 2018

1 reference

Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.

21 January 2018

1 reference

21 January 2018

1 reference

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

21 January 2018

1 reference

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

21 January 2018

1 reference

Bone marrow microenvironment and the identification of new targets for myeloma therapy

21 January 2018

1 reference

Oncogenic mutations of PIK3CA in human cancers

21 January 2018

1 reference

Can multiple myeloma become a curable disease?

21 January 2018

1 reference

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

21 January 2018

1 reference

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype

21 January 2018

1 reference

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

21 January 2018

1 reference

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

21 January 2018

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy

21 January 2018

1 reference

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

21 January 2018

1 reference

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12039

1 reference

10 September 2017

1 reference